Literature DB >> 14498814

Acceptability and availability of harm-reduction interventions for drug abuse in American substance abuse treatment agencies.

Harold Rosenberg1, Kristina T Phillips.   

Abstract

This study assessed acceptability, availability, and reasons for nonavailability of interventions designed to prevent drug use related harm by substituting pharmaceuticals for illicit drugs; facilitating detoxification; and reducing the occurrence of HIV transmission, relapse, and opiate overdose. A survey was mailed to a sample of 500 randomly selected American substance abuse treatment agencies. Of 435 potentially eligible respondents, 222 (51%) returned usable data. A subset of interventions--including harm reduction education, cue exposure therapy, needle exchange, substitute opiate prescribing, various detoxification regimes, and complementary therapies--were rated as somewhat or completely acceptable by 50% or more of the respondents. Regardless of their acceptability, listed interventions were generally not available from responding agencies; respondents typically attributed unavailability to lack of resources and inconsistency of an intervention with agency philosophy. (c) 2003 APA, all rights reserved

Entities:  

Mesh:

Year:  2003        PMID: 14498814     DOI: 10.1037/0893-164X.17.3.203

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  12 in total

1.  Problem-free drinking over 16 years among individuals with alcohol use disorders.

Authors:  Mark A Ilgen; Paula L Wilbourne; Bernice S Moos; Rudolf H Moos
Journal:  Drug Alcohol Depend       Date:  2007-08-23       Impact factor: 4.492

2.  Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats.

Authors:  Michael D Raleigh; Megan Laudenbach; Federico Baruffaldi; Samantha J Peterson; Michaela J Roslawski; Angela K Birnbaum; F Ivy Carroll; Scott P Runyon; Scott Winston; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-03-13       Impact factor: 4.030

3.  Development of a risk reduction intervention to reduce bacterial and viral infections for injection drug users.

Authors:  Kristina T Phillips; Jennifer K Altman; Karen F Corsi; Michael D Stein
Journal:  Subst Use Misuse       Date:  2012-09-27       Impact factor: 2.164

4.  Injection Drug Users' Perceived Barriers to Using Self-Initiated Harm Reduction Strategies.

Authors:  Erin E Bonar; Harold Rosenberg
Journal:  Addict Res Theory       Date:  2014-08-01

Review 5.  Expanding the continuum of substance use disorder treatment: Nonabstinence approaches.

Authors:  Catherine E Paquette; Stacey B Daughters; Katie Witkiewitz
Journal:  Clin Psychol Rev       Date:  2021-11-26

6.  Acceptability of nonabstinent treatment outcome goals among addiction treatment providers in Ukraine.

Authors:  Alan K Davis; Tetiana Nickelsen; Robert A Zucker; Erin E Bonar; Maureen A Walton
Journal:  Psychol Addict Behav       Date:  2018-04-12

7.  American counselors' acceptance of non-abstinence outcome goals for clients diagnosed with co-occurring substance use and other psychiatric disorders.

Authors:  Alan K Davis; Harold Rosenberg; Joseph A Rosansky
Journal:  J Subst Abuse Treat       Date:  2017-08-26

8.  Alpha test results for a Housing First eLearning strategy: the value of multiple qualitative methods for intervention design.

Authors:  Emily Q Ahonen; Dennis P Watson; Erin L Adams; Alan McGuire
Journal:  Pilot Feasibility Stud       Date:  2017-10-31

9.  A cross-sectional study of public attitudes towards safer drug use practices in British Columbia, Canada.

Authors:  Despina Tzemis; Jennifer Campbell; Margot Kuo; Jane A Buxton
Journal:  Subst Abuse Treat Prev Policy       Date:  2013-12-01

10.  Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.

Authors:  M D Raleigh; S J Peterson; M Laudenbach; F Baruffaldi; F I Carroll; S D Comer; H A Navarro; T L Langston; S P Runyon; S Winston; M Pravetoni; P R Pentel
Journal:  PLoS One       Date:  2017-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.